A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
Daniel J GeorgeSusan HalabiElisabeth I HeathA Oliver SartorGuru P SonpavdeDevika DasRhonda L BittingWilliam BerryPatrick HealyMonika AnandCarol WintersColleen RigganJulie KephartRhonda WilderKellie ShobeJulia RasmussenMatthew I MilowskyMark T FlemingJames BeardenMichael GoodmanTian ZhangMichael R HarrisonMegan McNamaraDadong ZhangBonnie L LaCroixRick A KittlesBrendon M PatiernoAlexander B SibleySteven R PatiernoKouros OwzarTerry HyslopJennifer A FreedmanAndrew J ArmstrongPublished in: Cancer (2021)
Multicenter prospective studies by race are feasible in men with mCRPC but require less restrictive eligibility. Despite higher comorbidity rates, Black patients demonstrated rPFS and OS similar to those of White patients and trended toward greater TTP and PSA declines, consistent with retrospective reports. Importantly, Black men may have higher side-effect rates than White men. This exploratory genome-wide analysis of TTP identified a possible candidate marker of ancestry-dependent treatment outcomes.